Opendata, web and dolomites

IMMUcan SIGNED

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUcan project word cloud

Explore the words cloud of the IMMUcan project. It provides you a very rough idea of what is the project "IMMUcan" about.

quality    gastric    lung    ethical    biological    ve    peptidogenomics    reproducibility    trials    independent    immunotherapy    microbiome    start    rationale    stored    population    plan    majority    contractual    ten    seq    patients    inhibitors    biobank    academia    predictive    material    cutting    host    generating    recruiting    processed    types    expert    combination    period    neck    head    running    samples    colorectal    breast    edge    perform    immucan    clinical    collection    assembled    oncology    relevance    analyze    proofed    checkpoints    inclusive    cytoff    stool    immunoprofiling    sustainability    centralized    cell    uniform    functioning    investigations    centers    blood    accessibility    failures    volumes    utilizing    proposes    pursue    database    na    immune    interaction    biomarker    technologies    tissue    data    platform    tumour    single    saliva    workflow    tumor    follow    rna    absence    sops    treatment    understand    tissues    immuno    cancers    academic    framework    iuml    industry    human    mobilize    therapies   

Project "IMMUcan" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL 

Organization address
address: Avenue E. Mounier 83
city: Brussels
postcode: 1200
website: www.eortc.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 34˙937˙500 €
 EC max contribution 17˙830˙000 € (51%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) coordinator 7˙246˙773.00
2    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 2˙749˙727.00
3    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 1˙712˙880.00
4    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 1˙460˙332.00
5    SIB INSTITUT SUISSE DE BIOINFORMATIQUE CH (GENEVE) participant 1˙323˙000.00
6    KING'S COLLEGE LONDON UK (LONDON) participant 765˙066.00
7    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 628˙320.00
8    UNIVERSITAT ZURICH CH (ZURICH) participant 573˙700.00
9    INSTITUT CURIE FR (PARIS) participant 410˙000.00
10    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 250˙000.00
11    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 190˙200.00
12    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 160˙000.00
13    LIGUE NATIONALE CONTRE LE CANCER FR (PARIS) participant 120˙000.00
14    CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD FR (LYON) participant 100˙000.00
15    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) participant 100˙000.00
16    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 20˙000.00
17    INSTITUT JULES BORDET BE (BRUXELLES) participant 20˙000.00
18    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
19    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
20    DE DUVE INSTITUTE BE (BRUXELLES) participant 0.00
21    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
22    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
23    INSTITUT DE RECHERCHE PIERRE FABRESAS FR (BOULOGNE BILLANCOURT) participant 0.00
24    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
25    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
26    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
27    OWKIN FRANCE FR (PARIS) participant 0.00
28    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More